DocMode e-Detailing

🎬 Brand Video — e-Detailing Module

PATIENT PRESENTATION

58-year-old female, T2DM for 12 years. Currently on Metformin 1g BD + Glipizide 5mg OD. HbA1c: 8.9%. BMI: 28.4. No CKD. Complains of 2-3 hypoglycaemic episodes/month. Employed as school teacher, long irregular hours.

KEY CLINICAL CHALLENGE

Persistent hyperglycaemia despite dual OHA with recurrent hypoglycaemia on SU. Patient reluctant for injectable therapy. Cardiovascular risk: moderate (borderline hypertension, family history of MI).

🤖

AIDE Clinical Insight: Based on patient profile — long T2DM duration, SU-related hypo episodes, BMI 28.4, and aversion to injectables — dual SGLT2/DPP4 add-on or extended-release basal formulations show strong evidence for HbA1c reduction with low hypo risk. Consider cardiometabolic profile before escalation.

This is AI-generated clinical information support, not a prescription directive.

Cardio-Diabetology Case 2: 63M, T2DM + established CVD, HbA1c 9.2% ▼ Expand

PATIENT PRESENTATION

63-year-old male, post-PTCA (2021), T2DM for 8 years. On Metformin 500mg BD, Atorvastatin 40mg, Aspirin 75mg. HbA1c: 9.2%. eGFR: 58 mL/min. Mild microalbuminuria.

KEY CLINICAL CHALLENGE

High cardiovascular risk requiring glucose-lowering with proven CV benefit. Mild CKD restricts some agents. Patient needs holistic cardiometabolic management with renal protection.

🤖

AIDE Clinical Insight: In established CVD with eGFR ≥45, SGLT2 inhibitors (empagliflozin, dapagliflozin) demonstrate CV mortality benefit (EMPA-REG, DECLARE-TIMI). GLP-1 RAs also indicated. Target HbA1c 7–7.5% to avoid hypoglycaemia risk post-MI.

💬 Your Clinical Feedback

VERIFIED HCP ONLY

💳

Educational Honorarium

For your time and genuine clinical insights.
Governed by your DocMode Professional Service Agreement.
Paid to your registered bank account within 7 working days.

COVERED BY

PSA Agreement

Ethics Approved

🤖

AIDE AI Assistant available
Based on the video and case content, AIDE can pre-fill initial responses. You review, edit, and submit your own views.

How would you rate the clinical relevance of GlycoBalance™ for your T2DM patients? *

Select one option

1 – Not Relevant

2

3 – Moderately

4

5 – Highly Relevant

In your practice, what is your primary concern when escalating OHA therapy? AI DRAFT AVAILABLE

Which patient profiles do you most commonly encounter in your practice? *

Newly diagnosed T2DM

Uncontrolled on Metformin

T2DM + CVD

T2DM + CKD

Elderly / frail

Obese T2DM

Any additional comments on the scientific content or unmet needs in T2DM management?

Declarations *

I confirm I am a registered medical practitioner and this feedback reflects my genuine clinical opinion, not prescribing intent.

I acknowledge this engagement is governed by my DocMode Professional Service Agreement and the applicable Ethics Board guidelines.

I understand this is an educational program and my feedback is used for scientific research purposes only.

✅ Review & Submit

🎬

Brand Video WatchedFull 4:32 viewed · 98% completion

📖

Scientific Booklet Reviewed6/6 pages · avg 42s per page

🔬

Case Studies Reviewed2 cases · AIDE insights viewed

💬

Feedback CompletedAll mandatory fields filled

UCPMP Audit Summary

✓ HCP Identity Verified (MCI Registry) ✓ PSA Agreement on File ✓ Voluntary Consent Recorded ✓ Ethics Board Ref: IEC-2024-DM-047 ✓ Content: Educational (Non-Promotional) ✓ Remuneration: Genuine Service (PSA)

Advancing Care in
Type 2 Diabetes Management

PATIENT PRESENTATION

KEY CLINICAL CHALLENGE

PATIENT PRESENTATION

KEY CLINICAL CHALLENGE

Educational Honorarium

Submission Complete, Dr. Sharma!

Advancing Care inType 2 Diabetes Management

PATIENT PRESENTATION

KEY CLINICAL CHALLENGE

PATIENT PRESENTATION

KEY CLINICAL CHALLENGE

Educational Honorarium

Submission Complete, Dr. Sharma!

Advancing Care in
Type 2 Diabetes Management